• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑转移非小细胞肺癌的治疗方案评估——基于概率语言 ELECTRE II 方法

Therapeutic Schedule Evaluation for Brain-Metastasized Non-Small Cell Lung Cancer with A Probabilistic Linguistic ELECTRE II Method.

机构信息

Business School, Sichuan University, Chengdu 610064, China.

School of Computer and Software, Nanjing University of Information Science and Technology, Nanjing 210044, China.

出版信息

Int J Environ Res Public Health. 2018 Aug 21;15(9):1799. doi: 10.3390/ijerph15091799.

DOI:10.3390/ijerph15091799
PMID:30134591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6163449/
Abstract

With the rapid development of modern medicine, therapeutic schedules of brain-metastasized non-small cell lung cancer (NSCLC) are expanding. To assist a patient who suffers from brain-metastasized NSCLC to select the most suitable therapeutic schedule, firstly, we establish an indicator system for evaluating the therapeutic schedules; then, we propose a probabilistic linguistic ELECTRE II method to handle the corresponding evaluation problem for the following reasons: (1) probabilistic linguistic information is effective to depict the uncertainty of the therapeutic process and the fuzziness of an expert's cognition; (2) the ELECTRE II method can deal with evaluation indicators that do not meet a fully compensatory relationship. Simulation tests on the parameters in the proposed method are provided to discuss their impacts on the final rankings. Furthermore, we apply the proposed method to help a patient with brain-metastasized NSCLC at the Sichuan Cancer Hospital and Institute to choose the optimal therapeutic schedule, and we present some sensitive analyses and comparative analyses to demonstrate the stability and applicability of the proposed method.

摘要

随着现代医学的快速发展,脑转移非小细胞肺癌(NSCLC)的治疗方案正在不断扩展。为了帮助患有脑转移 NSCLC 的患者选择最合适的治疗方案,我们首先建立了一个评估治疗方案的指标体系;然后,我们提出了一种概率语言 ELECTRE II 方法来处理相应的评估问题,原因如下:(1)概率语言信息有效地描述了治疗过程的不确定性和专家认知的模糊性;(2)ELECTRE II 方法可以处理不符合完全补偿关系的评价指标。我们提供了对所提出方法中的参数的仿真测试,以讨论它们对最终排名的影响。此外,我们将所提出的方法应用于帮助四川肿瘤医院和研究所的一位脑转移 NSCLC 患者选择最佳的治疗方案,并进行了一些敏感性分析和对比分析,以证明所提出方法的稳定性和适用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/fd3fc3f593db/ijerph-15-01799-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/dcfa5292e05b/ijerph-15-01799-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/38c381349107/ijerph-15-01799-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/bbfcbb38751e/ijerph-15-01799-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/af91bb2ae803/ijerph-15-01799-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/49da28edfd01/ijerph-15-01799-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/5d1a2c5f2e94/ijerph-15-01799-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/0282c60dd55d/ijerph-15-01799-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/fd3fc3f593db/ijerph-15-01799-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/dcfa5292e05b/ijerph-15-01799-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/38c381349107/ijerph-15-01799-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/bbfcbb38751e/ijerph-15-01799-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/af91bb2ae803/ijerph-15-01799-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/49da28edfd01/ijerph-15-01799-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/5d1a2c5f2e94/ijerph-15-01799-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/0282c60dd55d/ijerph-15-01799-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/6163449/fd3fc3f593db/ijerph-15-01799-g008.jpg

相似文献

1
Therapeutic Schedule Evaluation for Brain-Metastasized Non-Small Cell Lung Cancer with A Probabilistic Linguistic ELECTRE II Method.脑转移非小细胞肺癌的治疗方案评估——基于概率语言 ELECTRE II 方法
Int J Environ Res Public Health. 2018 Aug 21;15(9):1799. doi: 10.3390/ijerph15091799.
2
A hybrid DEMATEL-COPRAS method using interval-valued probabilistic linguistic term set for sustainable hydrogen fuel cell supplier of new energy vehicles.基于区间概率语言术语集的混合 DEMATEL-COPRAS 方法在新能源汽车可持续氢燃料电池供应商中的应用。
Environ Sci Pollut Res Int. 2023 Jun;30(29):74236-74264. doi: 10.1007/s11356-023-27470-8. Epub 2023 May 19.
3
Hesitant Fuzzy Linguistic Preference Utility Set and Its Application in Selection of Fire Rescue Plans.犹豫模糊语言偏好效用集及其在消防救援方案选择中的应用。
Int J Environ Res Public Health. 2018 Apr 3;15(4):664. doi: 10.3390/ijerph15040664.
4
Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.脑转移非小细胞肺癌(NSCLC)的管理——从局部治疗到新的全身治疗。
Cancer Treat Rev. 2017 Mar;54:122-131. doi: 10.1016/j.ctrv.2017.02.004. Epub 2017 Feb 17.
5
Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.来源于非小细胞肺癌脑转移的患者源性异种移植物是开发个体化靶向治疗的有价值的转化平台。
Clin Cancer Res. 2015 Mar 1;21(5):1172-82. doi: 10.1158/1078-0432.CCR-14-1589. Epub 2014 Dec 30.
6
Treatment recommendations by clinicians in stage I non-small cell lung cancer: A study of factors that influence the likelihood of accounting for the patient's preference.I期非小细胞肺癌临床医生的治疗建议:一项关于影响考虑患者偏好可能性因素的研究
Patient Educ Couns. 2016 Nov;99(11):1808-1813. doi: 10.1016/j.pec.2016.05.017. Epub 2016 Jun 18.
7
Multi-attribute decision making based on VIKOR with probabilistic linguistic term sets: An application to the risk evaluation of foreign direct investment.基于概率语言术语集的 VIKOR 的多属性决策:在外国直接投资风险评估中的应用。
PLoS One. 2024 Mar 1;19(3):e0294758. doi: 10.1371/journal.pone.0294758. eCollection 2024.
8
Incorporating linguistic, probabilistic, and possibilistic information in a risk-based approach for ranking contaminated sites.在基于风险的方法中纳入语言、概率和可能性信息,以对污染场地进行排名。
Integr Environ Assess Manag. 2010 Oct;6(4):711-24. doi: 10.1002/ieam.72.
9
Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation.不同局部治疗策略治疗非小细胞肺癌(NSCLC)脑转移(BMs)局限患者的疗效评估:单机构评估
Br J Radiol. 2017 Apr;90(1072):20170022. doi: 10.1259/bjr.20170022. Epub 2017 Mar 3.
10
Brain metastases from non-small cell lung carcinoma: Changing concepts for improving patients' outcome.非小细胞肺癌脑转移:改善患者预后的观念转变
Crit Rev Oncol Hematol. 2017 Aug;116:32-37. doi: 10.1016/j.critrevonc.2017.05.007. Epub 2017 May 20.

引用本文的文献

1
LogTODIM-PROMETHEE technique for development evaluation of school-enterprise cooperation from the perspective of collaborative education based on the probabilistic linguistic group decision-making.基于概率语言群体决策的协同教育视角下校企合作发展评价的LogTODIM-PROMETHEE技术
Heliyon. 2024 Jun 21;10(13):e33391. doi: 10.1016/j.heliyon.2024.e33391. eCollection 2024 Jul 15.

本文引用的文献

1
Mathematical modeling and computational prediction of cancer drug resistance.癌症药物耐药性的数学建模与计算预测。
Brief Bioinform. 2018 Nov 27;19(6):1382-1399. doi: 10.1093/bib/bbx065.
2
Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report.KLC1-ALK融合及MET基因扩增阳性非小细胞肺癌患者脑转移对克唑替尼的快速反应:一例报告
Cancer Biol Med. 2017 May;14(2):183-186. doi: 10.20892/j.issn.2095-3941.2017.0017.
3
The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.
表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)对表皮生长因子受体(EGFR)突变阳性的非小细胞肺癌脑转移的疗效。
Onco Targets Ther. 2017 Apr 27;10:2335-2340. doi: 10.2147/OTT.S129809. eCollection 2017.
4
Uncertainty of Physicians and Patients in Medical Decision Making.医生与患者在医疗决策中的不确定性
Biol Blood Marrow Transplant. 2017 Jun;23(6):865-869. doi: 10.1016/j.bbmt.2017.03.013. Epub 2017 Mar 14.
5
Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.脑转移非小细胞肺癌(NSCLC)的管理——从局部治疗到新的全身治疗。
Cancer Treat Rev. 2017 Mar;54:122-131. doi: 10.1016/j.ctrv.2017.02.004. Epub 2017 Feb 17.
6
Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.韩国晚期非小细胞肺癌患者表皮生长因子受体突变伴随诊断检测及一线靶向治疗的经济学评估
PLoS One. 2016 Aug 2;11(8):e0160155. doi: 10.1371/journal.pone.0160155. eCollection 2016.
7
Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT).玻璃微球钇-90 选择性内放射治疗(SIRT)肝内胆管癌时 Choi 标准与实体瘤疗效评价标准(RECIST)的比较
Eur J Radiol. 2016 Aug;85(8):1445-52. doi: 10.1016/j.ejrad.2016.05.020. Epub 2016 Jun 2.
8
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.非小细胞肺癌(NSCLC)患者中,未治疗或病情进展的中枢神经系统转移患者对纳武单抗的颅内反应。
Lung Cancer. 2016 Aug;98:114-117. doi: 10.1016/j.lungcan.2016.05.031. Epub 2016 May 31.
9
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.帕博利珠单抗用于治疗黑色素瘤或非小细胞肺癌且伴有未经治疗的脑转移患者:一项非随机、开放标签的2期试验的早期分析
Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.
10
Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.中国埃克替尼与吉非替尼作为晚期非小细胞肺癌二线治疗的基于试验的成本-效用分析
PLoS One. 2016 Mar 25;11(3):e0151846. doi: 10.1371/journal.pone.0151846. eCollection 2016.